This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jakupciak, J. P. Articles by O’Connell, C. D. Search for Related Content PubMed PubMed Citation Articles by Jakupciak, J. P. Articles by O’Connell, C. D.

JMD 2005, Vol. 7, No. 2
Copyright © 2005 American Society for Investigative Pathology & Association for Molecular Pathology

Mitochondrial DNA as a Cancer Biomarker

John P. Jakupciak^*, Wendy Wang, Maura E. Markowitz, Delphine Ally, Michael Coble^*, Sudhir Srivastava, Anirban Maitra, Peter E. Barker^*, David Sidransky and Catherine D. O’Connell^*

From the Biotechnology Division, * National Institute of Standards and Technology, Gaithersburg, Maryland; the Early Detection Research Network, National Cancer Institute, Rockville, Maryland; Geo-Centers, Incorporated, Newton, Massachusetts; and The Johns Hopkins University School of Medicine, Baltimore, Maryland

As part of a national effort to identify biomarkers for the early detection of cancer, we developed a rapid and high-throughput sequencing protocol for the detection of sequence variants in mitochondrial DNA. Here, we describe the development and implementation of this protocol for clinical samples. Heteroplasmic and homoplasmic sequence variants occur in the mitochondrial genome in patient tumors. We identified these changes by sequencing mitochondrial DNA obtained from tumors and blood from the same individual. We confirmed previously identified primary lung tumor changes and extended these findings in a small patient cohort. Eight sequence variants were identified in stage I to stage IV tumor samples. Two of the sequence variants identified (22%) were found in the D-loop region, which accounts for 6.8% of the mitochondrial genome. The other sequence variants were distributed throughout the coding region. In the forensic community, the sequence variations used for identification are localized to the D-loop region because this region appears to have a higher rate of mutation. However, in lung tumors the majority of sequence variation occurred in the coding region. Hence, incomplete mitochondrial genome sequencing, designed to scan discrete portions of the genome, misses potentially important sequence variants associated with cancer or other diseases.

This article has been cited by other articles:

				L. Jacobs, M. Gerards, P. Chinnery, J. Dumoulin, I. de Coo, J. Geraedts, and H. Smeets mtDNA point mutations are present at various levels of heteroplasmy in human oocytes Mol. Hum. Reprod., March 1, 2007; 13(3): 149 - 154*. [Abstract] [Full Text] [PDF]

				S. Zhou, K. Kassauei, D. J. Cutler, G. C. Kennedy, D. Sidransky, A. Maitra, and J. Califano An Oligonucleotide Microarray for High-Throughput Sequencing of the Mitochondrial Genome J. Mol. Diagn., September 1, 2006; 8(4): 476 - 482. [Abstract] [Full Text] [PDF]

				R. L. Parr, G. D. Dakubo, K. A. Crandall, J. Maki, B. Reguly, A. Aguirre, R. Wittock, K. Robinson, J. S. Alexander, M. A. Birch-Machin, et al. Somatic Mitochondrial DNA Mutations in Prostate Cancer and Normal Appearing Adjacent Glands in Comparison to Age-Matched Prostate Samples without Malignant Histology J. Mol. Diagn., July 1, 2006; 8(3): 312 - 319. [Abstract] [Full Text] [PDF]